CL2010001618A1 - Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades. - Google Patents

Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades.

Info

Publication number
CL2010001618A1
CL2010001618A1 CL2010001618A CL2010001618A CL2010001618A1 CL 2010001618 A1 CL2010001618 A1 CL 2010001618A1 CL 2010001618 A CL2010001618 A CL 2010001618A CL 2010001618 A CL2010001618 A CL 2010001618A CL 2010001618 A1 CL2010001618 A1 CL 2010001618A1
Authority
CL
Chile
Prior art keywords
cyclic
pharmaceutical composition
factor
arteriosclerosis
inhibitors
Prior art date
Application number
CL2010001618A
Other languages
English (en)
Inventor
Ho Young Song
Dae Yon Lee
Hee Sock Park
Sung Yoon Baek
Sang Eun Chae
Sang Hui Jo
Yeon Ok Kim
Hyang Sook Lee
Ju Hyun Park
Tan Kyo Park
Sung Ho Woo
Young Zu Kim
Young Lag Cho
Original Assignee
Legochem Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Bioscience Ltd filed Critical Legochem Bioscience Ltd
Publication of CL2010001618A1 publication Critical patent/CL2010001618A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DERIVADOS DE OXAZOLIDINONA SUSTITUIDA CON UN GRUPO AMIDOXIMA CICLICA O AMIDRAZONA CÍCLICA Y SUS SALES ACEPTADAS PARA USO FARMACÉUTICO, DONDE A ES UN RESIDUO SELECCIONADO  (FIGURA 1) INHIBIDORES DEL FACTOR XA; COMPOSICIÓN FARMACÉUTICA QUE LOS CONTIENEN; Y SU USO EN EL TRATAMIENTO Y PREVENCION DE LA TROMBOEMBOLIA, TUMORES Y COMO ANTICOAGULANTES.  
CL2010001618A 2008-07-03 2010-12-29 Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades. CL2010001618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080064178A KR100898361B1 (ko) 2008-07-03 2008-07-03 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물

Publications (1)

Publication Number Publication Date
CL2010001618A1 true CL2010001618A1 (es) 2011-10-28

Family

ID=40862256

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001618A CL2010001618A1 (es) 2008-07-03 2010-12-29 Compuestos derivados de oxazolidinona sustituida con un grupo amidoxima ciclica o amidrazona ciclica, inhibidores del factor xa; composicion farmaceutica; y su uso para prevenir o tratar trombosis, infarto al miocardio, arteriosclerosis, entre otras enfermedades.

Country Status (17)

Country Link
US (1) US8178525B2 (es)
EP (1) EP2307407B1 (es)
JP (1) JP5325289B2 (es)
KR (1) KR100898361B1 (es)
CN (1) CN102083825B (es)
AU (1) AU2009266631B2 (es)
BR (1) BRPI0915326B8 (es)
CA (1) CA2728350C (es)
CL (1) CL2010001618A1 (es)
ES (1) ES2566755T3 (es)
IL (1) IL210384A (es)
MX (1) MX2010013969A (es)
MY (1) MY165573A (es)
NZ (1) NZ590315A (es)
RU (1) RU2468024C2 (es)
UA (1) UA97598C2 (es)
WO (1) WO2010002115A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101023174B1 (ko) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
KR101037051B1 (ko) 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 (ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
KR101037052B1 (ko) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
GEP20156397B (en) * 2011-05-06 2015-11-10 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Process for the preparation of a rivaroxaban and intermediates formed in said process
US8877628B2 (en) 2012-07-12 2014-11-04 Micron Technologies, Inc. Methods of forming nano-scale pores, nano-scale electrical contacts, and memory devices including nano-scale electrical contacts, and related structures and devices
CN110407827B (zh) * 2014-07-18 2023-05-23 株式会社绿十字 Gcc-4401c的晶形和包含所述晶形的药物组合物
CN114591337A (zh) * 2022-03-31 2022-06-07 武汉工程大学 一种吡唑并[1,2-a][1,2,4]三嗪-3,6-二酮衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10342570A1 (de) 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
US20080051578A1 (en) * 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Also Published As

Publication number Publication date
EP2307407B1 (en) 2016-03-16
NZ590315A (en) 2012-11-30
BRPI0915326A2 (pt) 2015-08-04
RU2011103766A (ru) 2012-08-10
CA2728350C (en) 2013-09-24
WO2010002115A2 (en) 2010-01-07
BRPI0915326B8 (pt) 2021-05-25
RU2468024C2 (ru) 2012-11-27
UA97598C2 (ru) 2012-02-27
AU2009266631A1 (en) 2010-01-07
CN102083825B (zh) 2014-07-30
JP2011526624A (ja) 2011-10-13
ES2566755T3 (es) 2016-04-15
AU2009266631B2 (en) 2012-03-15
CN102083825A (zh) 2011-06-01
MY165573A (en) 2018-04-05
CA2728350A1 (en) 2010-01-07
US8178525B2 (en) 2012-05-15
US20110112083A1 (en) 2011-05-12
KR100898361B1 (ko) 2009-05-20
WO2010002115A3 (en) 2010-03-11
EP2307407A2 (en) 2011-04-13
IL210384A (en) 2014-09-30
IL210384A0 (en) 2011-03-31
BRPI0915326B1 (pt) 2021-04-06
JP5325289B2 (ja) 2013-10-23
EP2307407A4 (en) 2011-08-24
MX2010013969A (es) 2011-05-02

Similar Documents

Publication Publication Date Title
AR120700A1 (es) Inhibidores de kras g12c
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
NI200700320A (es) Inhibidores de la actividad akt
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
CR20110224A (es) Pirazolopirimidina inhibidor jak compuestos y metodos
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
PA8828201A1 (es) Compuestos triazina como inhibidores mtor y quinasa p13
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
AR059066A1 (es) Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2011000159A1 (es) Compuestos derivados de 1,3-oxazin-2-ona, inhibidores de 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.
CU20110052A7 (es) Compuestos orgánicos
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CL2022000835A1 (es) Inhibidor de diacilglicerol aciltransferasa 2
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CL2011001093A1 (es) Compuestos derivados de 4-[2-(2-fluorofenoximetil)fenil]piperidina, inhibidores de la recaptacion de serotonina y norepinefrina; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para tratar el dolor neuropatico, fibromialgia, trastorno depresivo y obesidad entre otras.
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.